Sign up to save your podcasts
Or
Share #42 Regenerative Medicine? How two companies are attacking nerve damage.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
#42 Regenerative Medicine? How two companies are attacking nerve damage.
This episode on BioTech IQ is actually a recording of two separate interviews. In the first half of the show I interview Pete Mariani who is the CFO of Axogen, Inc. Pete has strong experience in public markets experience including successful raises of equity, debt and strategic financing; driving strong, consistent investor communication and strategies; and establishing solid SEC reporting structures.
The second guest is Robert w. Mays, Ph.D, Co-Founder and Vice President of Regenerative Medicine and Neuroscience programs at Athersys, Inc. Dr. Mays has more than 25 years of experience in technology development, drug discovery and translational stem cell experience.
https://thebiotechiqpodcast.com/
Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
View all episodes
By Ammon RiveraThis episode on BioTech IQ is actually a recording of two separate interviews. In the first half of the show I interview Pete Mariani who is the CFO of Axogen, Inc. Pete has strong experience in public markets experience including successful raises of equity, debt and strategic financing; driving strong, consistent investor communication and strategies; and establishing solid SEC reporting structures.
The second guest is Robert w. Mays, Ph.D, Co-Founder and Vice President of Regenerative Medicine and Neuroscience programs at Athersys, Inc. Dr. Mays has more than 25 years of experience in technology development, drug discovery and translational stem cell experience.
https://thebiotechiqpodcast.com/
Check me out on LinkedIn https://www.linkedin.com/in/ammonr/